Posts in category Analyst News


This Analyst Sees Good Opportunity Ahead for Helios and Matheson Analytics Inc (HMNY) and MoviePass

Maxim’s Brian Kinstlinger is bullish on HMNY after 52% owned platform MoviePass sets loose new promotion that could soon bring subscribers past 1 million.

Read more

Valeant Pharmaceuticals Intl Inc (VRX) Gets a Price Target Trim on Uncertainty Circling Legal Liabilities

Deutsche Bank’s Gregg Gilbert is concerned about the unpredictability of VRX’s legal hurdles that lie ahead.

Read more

Foot Locker, Inc. (FL) Rockets; Analyst Erinn Murphy Takes a Wait-And-See Approach

FL stock makes its highest leap in 40 years on back of earnings beat, but yet again, Piper Jaffray’s Erinn Murphy doesn’t seem to be impressed.

Read more

Tesla Inc (TSLA): Analyst Highlights Competitive Advantages at Play

Guggenheim’s Rob Cihra believes TSLA’s leading technology and Gigafactory are key, not-so-secret weapons.

Read more

Top Analyst Lifts Price Target on Applied Materials, Inc. (AMAT) on Back of ‘Stellar Quarterly Execution’

Applied Materials is well positioned for multi-yr gains, says top analyst Craig Ellis.

Read more

Will Apple Inc. (AAPL) Be the First Member of the ‘Trillion-Dollar Market Cap Club’?

GBH Insights’ Daniel Ives predicts AAPL could sell more iPhones this time around than even its best during the iPhone 6 upgrade cycle.

Read more

This Analyst Advocates That xG Technology Inc (XGTI) Demand Continues to Be “Solid” Despite Weak 3Q Performance

Maxim’s Brian Kinstlinger looks for a revenue comeback from XGTI.

Read more

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Gets a Price Target Reduction: Can It Hold Its Ground Short-Term?

Mizuho’s Irina Rivkind Koffler says if TEVA can stabilize its business, it could evade a downgrade to high yield.

Read more

Analyst Neil Maruoka Buys on Aurinia Pharmaceuticals Inc (AUPH) for Attractive Worldwide Partnering Potential in Competitive LN Landscape

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) served its third quarter earnings on Tuesday, but to Canaccord analyst …

Read more

Analyst Colin Rusch Sets Neutral Expectations on Tesla Inc (TSLA) Model 3 and Tonight’s Semi Debut

Oppenheimer’s Colin Rusch angles for “intrigue,” but recognizes challenges still face TSLA.

Read more